Attached files
| file | filename |
|---|---|
| 10-Q - ENZON PHARMACEUTICALS, INC. | c66462_10-q.htm |
| EX-32.1 - ENZON PHARMACEUTICALS, INC. | c66462_ex32-1.htm |
| EX-10.8 - ENZON PHARMACEUTICALS, INC. | c66462_ex10-8.htm |
| EX-31.1 - ENZON PHARMACEUTICALS, INC. | c66462_ex31-1.htm |
| EX-31.2 - ENZON PHARMACEUTICALS, INC. | c66462_ex31-2.htm |
| EXCEL - IDEA: XBRL DOCUMENT - ENZON PHARMACEUTICALS, INC. | Financial_Report.xls |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. §1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
|
|
|
|
|
In connection with the Quarterly Report on Form 10-Q of Enzon Pharmaceuticals, Inc. (the Company) for the period ended June 30, 2011 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Ana Stancic, Senior Vice President, Finance and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge: |
||
|
|
|
|
|
|
1. |
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
|
|
|
|
|
2. |
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
|
|
|
|
|
August 5, 2011 |
|
/s/Ana Stancic |
|
|
|
|
|
|
|
Ana Stancic |
34